



<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/500,270 ✓
		Filing Date	December 23, 2002
		First Named Inventor	Corrado Spadafora
		Group Art Unit	Unknown
		Examiner Name	Unknown
Total Number of Pages in This Submission	14	Attorney Docket Number	27419/200

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Supplemental Preliminary Amendment <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request (\$510.00) <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement (\$____) <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Response to Notification of Missing Requirements Under 35 U.S.C. 371 <input checked="" type="checkbox"/> A copy of the Notification of Missing Requirements Under 35 U.S.C. 371	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input checked="" type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition (\$____) <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Revocation and Power of Attorney (Assignee) <input type="checkbox"/> Terminal Disclaimer (\$____) <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (\$____) (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input type="checkbox"/> Request for Corrected Filing Receipt with Enclosures <input checked="" type="checkbox"/> A self-addressed, prepaid postcard for acknowledging receipt <input checked="" type="checkbox"/> Check in the amount of \$510.00 <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks	<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 14-1138 for the above identified docket number.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name Andrew K. Gonsalves, Esq. Nixon Peabody LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051 Telephone: (585) 263-1658 Fax: (585) 263-1600	Signature 
Date July 21, 2005	Registration No. 48,145

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input checked="" type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) _____	
Date July 21, 2005	Signature  Jo Ann Whalen Typed or printed name

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Spadafora et al.	)	Examiner:
			)	Unknown
Serial No.	:	10/500,270	)	
			)	Art Unit:
Cnfrm. No.	:	9338	)	Unknown
			)	
Filed	:	December 23, 2002	)	
			)	
For	:	NON-NUCLEOSIDIC INHIBITORS OF	)	
		REVERSE TRANSCRIPTASE AS	)	
		ANTAGONISTS OF CELL	)	
		PROLIFERATION AND INDUCERS OF	)	
		CELL DIFFERENTIATION	)	

RESPONSE TO THE NOTIFICATION OF MISSING REQUIREMENTS  
UNDER 35 U.S.C. § 371

## Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. § 371 (mailed March 1, 2005), applicants hereby submit a signed Combined Declaration and Power of Attorney form in compliance with 37 C.F.R. §§ 1.497(a) and (b). If any fees are due in regard to the submission of this executed Combined Declaration and Power of Attorney, please charge our Deposit Account No. 14-1138. Applicants are also submitting herewith a Revocation and Power of Attorney (dated June 30, 2005).


The Notification of Missing Requirements Under 35 U.S.C. § 371 states that applicants must furnish a Sequence Listing and the appropriate accompanying statements in compliance with 37 C.F.R. §§ 1.821-1.825. Applicants respectfully submit that no such Sequence Listing and accompanying statements are required, because there are no nucleotide or amino acid sequences contained in the present application.

Applicants are also submitting herewith a Supplemental Preliminary Amendment to place claim 9 in proper multiple dependent form. Applicants note that no additional fees are required with respect to this amendment, because the multiple dependent claim fee was properly paid at the time of filing.

In view of all of the foregoing, applicants submit that this case is complete and ready for examination by the U.S. Patent and Trademark Office, and such examination is earnestly solicited.

Respectfully submitted,

Date: July 21, 2005

  
\_\_\_\_\_  
Andrew K. Gonsalves  
Registration No. 48,145


NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1658  
Facsimile: (585) 263-1600

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

- ☒ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450
- ☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) \_\_\_\_\_.

July 21, 2005  
Date

  
\_\_\_\_\_  
Signature

Jo Ann Whalen  
Type or Print Name



## UNITED STATES PATENT AND TRADEMARK OFFICE

Rec'd PCT/PTO

25 JUL 2005

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO.

10/500,270

FIRST NAMED APPLICANT

Corrado Spadafora

ATTY. DOCKET NO.

11340-005-999

INTERNATIONAL APPLICATION NO.

PCT/EP02/14727

I.A. FILING DATE

12/23/2002

PRIORITY DATE

12/24/2001

20583

JONES DAY

222 EAST 41ST ST

NEW YORK, NY 10017

FILED  
Nixon Peabody LLP

APR 01 2005

FILE  
DRT

27419/200 pak

Response Due

Sequence Listing Due

May 1, 2005

CONFIRMATION NO. 9338

371 FORMALITIES LETTER

\*OC000000015300476\*

Date Mailed: 03/01/2005

# NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 06/24/2004
- Copy of the International Search Report filed on 06/24/2004
- Preliminary Amendments filed on 06/24/2004
- Information Disclosure Statements filed on 06/24/2004
- Oath or Declaration filed on 06/24/2004
- Biochemical Sequence Listing filed on 06/24/2004
- Small Entity Statement filed on 06/24/2004
- Request for Immediate Examination filed on 06/24/2004
- U.S. Basic National Fees filed on 06/24/2004
- Priority Documents filed on 06/24/2004

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
  - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
  - CLAIM #9 ON PRE AMDT IS IMPROPER MULITABLE.

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/500,270	PCT/EP02/14727	11340-005-999